Seelos Therapeutics Faces Liquidation Following Court-Approved Asset Sale
Veröffentlicht: 11.10.2025 um 10:09 Uhr, Redaktion boerse-global.de
A New York bankruptcy judge has authorized the sale of Seelos Therapeutics’ remaining assets for $22 million, effectively concluding the biotechnology firm’s protracted financial collapse. The September 17 ruling approved a credit bid from GLD Debt Acquisition, which had previously acquired the company’s secured debt obligations.
The asset disposal faced significant opposition from unsecured creditors’ committees, requiring additional concessions to proceed. Objections were ultimately resolved through a $100,000 cash payment plus $25,000 allocated for contractual expenses. Certain assets were excluded from the primary sale and are scheduled for separate auctions, with anticipated proceeds between $175,000 and $200,000. These amounts represent minimal recovery compared to outstanding liabilities.
Regulatory Demotion and Trading Restrictions
The company’s decline accelerated in October 2024 when Nasdaq delisted Seelos shares... Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
